Beta phenethylalamine

Beta-Phenylethylamine (β-PEA): A Comprehensive Reference

1. Identity and Chemical Characterization

PEA is known under a variety of names including β-phenylethylamine, β-phenethylamine, and phenylethylamine. According to the International Union of Pure and Applied Chemistry (IUPAC), the proper name of PEA is 2-phenylethylamine. Additional synonyms used in commerce and scientific literature include: 1-amino-2-phenylethane, benzeneethanamine, PEA, phenethylamine HCl, and phenethylamine hydrochloride.

Its molecular formula is C₈H₁₁N. PEA has a molecular weight of 121.17964 g/mol, a high solubility in water, and a short half-life. The lack of a methyl group distinguishes PEA from its structural relative amphetamine. β-phenylethylamine (PEA) is a trace amine, recently regarded as a neurotransmitter rather than merely a neuromodulator, whose chemical structure is similar to amphetamine, mescaline, and the catecholamines.

In the human body, PEA has a neuromodulator/neurotransmitter role and is known as a trace amine due to its low quantity relative to classical biogenic amines. The expression "trace amine" is used to refer to a group of amines that occur at much lower intra- and extracellular concentrations than the chemically and functionally related biogenic amines and neurotransmitters epinephrine, norepinephrine, serotonin, dopamine, and histamine.

Natural Sources

PEA can be found in many algae, fungi, and bacteria, as well as a variety of different plant species. Foods that naturally contain this molecule include various plants in the family Leguminosae, which is composed of trees, shrubs, vines, herbs such as clover, nuts and seeds like almonds, flaxseeds, and walnuts, and legumes such as soybeans, lentils, chickpeas, and green peas. Chocolate is considered one of the best dietary sources, and levels increase in cocoa beans when they are fermented and roasted.

Aromatic amines such as tyramine and β-phenylethylamine are abundantly detected in fermented food products including cheese, wine, chocolate, and traditional fermented foodstuffs consumed universally. PEA is found in fermented dairy products such as cheese (up to 61 mg/kg), in alcoholic beverages such as beer (up to 8.4 mg/kg), and in vegetables and vegetable products (up to 9.3 mg/kg), including cocoa beans and cocoa-containing foods such as chocolate.

Aphanizomenon flos-aquae (AFA), a concentrated blue-green algae, has been found to have very high levels of phenylethylamine; it contains many times more PEA than chocolate.

Endogenous Biosynthesis

β-PEA is biosynthesized from the amino acid L-phenylalanine by enzymatic decarboxylation via the enzyme aromatic L-amino acid decarboxylase (AADC). Aromatic amino-acid decarboxylase converts phenylalanine to phenylethylamine; this is the same enzyme that converts phenylalanine into dopamine. In particular, β-PEA is synthesized within nigrostriatal and mesolimbic dopamine regions, such as the striatum and nucleus accumbens, and the highest level of β-PEA is found in these brain regions.

Common Forms and Preparations

PEA supplements come in several forms, including powders and capsules. Some PEA supplements contain hydrochloride (HCl), which is added to make it easier for the body to digest PEA. Dietary supplements formulated for the sustained release of PEA nitrate and/or nitrite have been developed, and may include a food product or liquid product. The free-base form is a colorless liquid that is unstable upon prolonged air exposure. The hydrochloride salt is the most commonly encountered solid form in commercial dietary supplements.

2. Traditional and Historical Use

PEA as an isolated compound was not part of any pre-modern pharmacopeia; however, the cacao plant — its richest culinary source — has a well-documented history of traditional use. The aphrodisiac story of chocolate is ancient, going back to 1519 and the first visit of the Spanish explorer Hernando Cortes to Mexico. Cortes encountered the Aztec preparation of "chocolatl" — the "food of the gods" — which was described as able to "stimulate amorous adventures." On his return to Spain, he presented Emperor Charles V with a sample of cocoa.

In 1624, a French theologian condemned the consumption of chocolate in convents, claiming the beverage inflamed passionate feelings. In the 18th century, chocolate figured prominently among foods considered to incite sexual activity. In 1702, in his Traité des Aliments, Louis Lémery wrote: "Its stimulating properties are likely to excite the passions of Venus." Its putative anti-depressant effects were observed as early as the 17th century.

Historically, PEA has garnered attention for its mood-enhancing and stimulating properties. Ancient medicinal practices, particularly in regions where cacao was prized, often attributed uplifting and energizing effects to foods rich in PEA, using them as natural remedies for feelings of low mood or fatigue. It should be noted, however, that the classical Mesoamerican and European attribution of mood and aphrodisiac effects to cacao was not specifically attributed to PEA by those traditions; PEA itself was not chemically identified until the modern era.

In the early 20th century, researchers began to isolate and study PEA, discovering its role as a neuromodulator in the human brain, contributing to the release of dopamine and other feel-good neurotransmitters. Evidence that β-phenylethylamine (PEA) is a physiological constituent in the mammalian brain and the assumption that it might work as a stimulant in the CNS goes back to the early 1970s (Sabelli and Giardina, 1973). Awareness of low levels of PEA being linked to depression led Michael Leibowitz in the late 1970s to speculate that depression in some patients had been caused by a deficiency in PEA, following observation that romance-deprived patients improved after treatment with a monoamine oxidase inhibitor (MAOI). This was how phenylethylamine became popularly dubbed the "love chemical."

3. Key Constituents, Active Compounds, and Mechanisms of Action

Beta-phenylethylamine is itself the primary bioactive entity in the supplement context. Its activity arises from several interlocking mechanisms:

Trace Amine-Associated Receptor 1 (TAAR1) Agonism

The molecular mechanism of the trace amines involves binding to a novel G protein-coupled receptor called TAAR (trace amine-associated receptor), the most studied of which, TAAR1, can be activated by the drug amphetamine as well. Trace amine-associated receptor 1 (TAAR1), the most well-characterized receptor in the TAAR family, has been shown to be potently activated by trace amines like tyramine and PEA.

Although its molecular interactions and downstream targets have not been fully elucidated, TAAR1 activation triggers accumulation of intracellular cAMP, modulates PKA and PKC signaling, and interferes with the β-arrestin2-dependent pathway via G protein-independent mechanisms. TAAR1 is uniquely positioned to exert direct control over dopamine and serotonin neuronal firing and release, which has profound implications for understanding the pathophysiology of a range of neuropsychiatric disorders that involve aminergic dysregulation, including Parkinson's disease, schizophrenia, mood disorders, and addiction.

Monoamine Transporter Modulation

TAAR1 activation by beta-PEA significantly inhibited uptake and induced efflux of [³H]dopamine, [³H]norepinephrine, and [³H]serotonin in transfected cells. The effect of beta-PEA on efflux was blocked by transporter inhibitors in either transfected cells or wild-type mouse synaptosomes. TAAR1 signaling was not affected by monoamine autoreceptors at trace amine exposure levels. These results reveal that beta-PEA alters monoamine transporter function via interacting with TAAR1 but not monoamine autoreceptors.

It is believed that the locomotor-stimulating action of beta-PEA, much like amphetamine, depends on its ability to increase extracellular dopamine concentrations owing to reversal of the direction of dopamine transporter (DAT)-mediated dopamine transport. Beta-PEA can also bind directly to recently identified G protein-coupled receptors, but the physiological significance of this interaction is not fully clear.

Dopamine System Interactions

It is known that β-PEA inhibits the uptake of dopamine and promotes the release of dopamine in the mesocorticolimbic pathway. In microdialysis studies, beta-PEA administered either systemically or locally via intrastriatal infusion produced a pronounced outflow of striatal dopamine in wild-type mice, whereas no increase was detected in mice lacking the dopamine transporter.

Metabolism: The MAO-B Problem

PEA was characterized as a substrate for type B monoamine oxidase (MAO-B). The monoamine oxidase B (MAO-B) enzyme in the body selectively metabolises phenylethylamine to phenylacetic acid, and it has been reported that the concentration of phenylacetic acid is significantly reduced in the urine, plasma, and cerebrospinal fluid of depressed patients. In humans, PEA is metabolized by phenylethanolamine N-methyltransferase (PNMT), monoamine oxidase A (MAO-A), monoamine oxidase B (MAO-B), the semicarbazide-sensitive amine oxidases (SSAOs) AOC2 and AOC3, flavin-containing monooxygenase 3 (FMO3), and aralkylamine N-acetyltransferase (AANAT). β-Phenylacetic acid is the primary urinary metabolite of phenylethylamine and is produced via monoamine oxidase metabolism and subsequent aldehyde dehydrogenase metabolism.

Orally ingested PEA may be inactivated on account of extensive first-pass metabolism by monoamine oxidase (MAO) into phenylacetic acid, preventing significant concentrations from reaching the brain. This has important implications for oral supplementation: without co-administration of a MAO-B inhibitor, the vast majority of an oral dose is degraded before reaching the central nervous system.

β-PEA is heterogeneously distributed throughout the mammalian brain in trace concentrations of generally about 2 nM and is extensively and rapidly metabolized by MAO-B. Treatment with clinically relevant doses of R-(–)-deprenyl (up to 10 mg) that selectively inhibit MAO-B can result in a nearly 100-fold increase in the urinary excretion of β-PEA. Such doses of R-(–)-deprenyl have also been shown to produce a 1,000- to 3,000-fold increase in levels of the monoamine in post-mortem brains taken from Parkinsonian patients treated with R-(–)-deprenyl.

The PEA Neuronal System

The PEA neuron may have aromatic L-amino acid decarboxylase (AADC) as a synthesizing enzyme, TAAR1 as a receptor, and MAO-B as a degrading enzyme. Levels of trace amines are altered in human disorders such as schizophrenia, depression, attention deficit/hyperactivity disorder, Parkinsonism, Rett syndrome, migraine, phenylketonuria, hepatic encephalopathy, and hypertension, and trace amines are believed to play a role in these conditions.

4. Scientific Evidence by Area of Use

4.1 Depression and Mood Disorders

Background hypothesis: It has been proposed that PEA deficit may be the cause of a common form of depressive illness. The concentration of phenylacetic acid — the primary metabolite of PEA — is significantly reduced in the urine, plasma, and cerebrospinal fluid of depressed patients, suggesting reduced PEA turnover in depression.

Key clinical study (Sabelli et al., 1996): Phenylethylamine (PEA), an endogenous neuroamine, increases attention and activity in animals and has been shown to relieve depression in 60% of depressed patients. It has been proposed that PEA deficit may be the cause of a common form of depressive illness. Fourteen patients with major depressive episodes that responded to PEA treatment (10–60 mg orally per day, with 10 mg/day selegiline to prevent rapid PEA destruction) were reexamined 20 to 50 weeks later. The antidepressant response had been maintained in 12 patients. Effective dosage did not change with time. There were no apparent side effects.

PEA improves mood as rapidly as amphetamine but does not produce tolerance. In the same Sabelli protocol, patients had been successfully treated with PEA plus selegiline, with the depressive episode in full remission for one month or more. All patients received selegiline (5 mg twice daily) plus 10–60 mg of PEA per day according to clinical response, administered in divided doses (2.5–20 mg) before 5:00 PM to avoid interfering with sleep.

Contradictory evidence: Some results suggest that depression is not associated with a generalized PEA deficit and that phenylacetic acid reductions previously reported in depressed patient populations may not reflect a PEA abnormality.

Affective correlations in healthy subjects: Urinary PEA excretion was determined in 32 drug-free healthy volunteers assessed with the MMPI personality inventory. A significant positive correlation between PEA and hypomania (r = 0.50; P < 0.05) and a significant negative correlation between PEA and depression (r = −0.58; P < 0.01) was observed in the female subgroup. Furthermore, PEA correlated significantly negatively with hypochondriasis, paranoia, and social introversion. These results were described as the first evidence in normal individuals that PEA might play a role in the modulation of affective behaviour.

Evidence strength: Human clinical evidence for PEA in depression is very limited — primarily a small open-label trial (n=14) by Sabelli et al. published in 1996. No large randomized, double-blind, placebo-controlled trials have been conducted. The evidence base is preliminary and insufficient to establish clinical efficacy on its own.

4.2 Attention Deficit Hyperactivity Disorder (ADHD)

Reviews covering ADHD and phenethylamine indicate that several studies have found abnormally low urinary phenethylamine concentrations in ADHD individuals when compared with controls. In treatment-responsive individuals, amphetamine and methylphenidate greatly increase urinary phenethylamine concentration. An ADHD biomarker review also indicated that urinary phenethylamine levels could be a diagnostic biomarker for ADHD.

Urinary excretion (24-hr) of beta-phenylethylamine (PEA), phenylacetic acid (PAA), phenylalanine, and p-tyrosine, and plasma levels of PAA, phenylalanine, and tyrosine were examined in 18 normal children and 26 children diagnosed as having ADHD. Urinary excretion of free and total PEA was significantly lower in the ADHD patients, and plasma levels of phenylalanine and tyrosine were also decreased in the ADHD subjects compared with the normal controls.

In 22 children with ADHD treated with methylphenidate and further divided into methylphenidate responders (n=18) and nonresponders (n=4), beta-phenylethylamine levels significantly increased after methylphenidate therapy in responders, whereas they did not increase in nonresponders.

The trace amine β-phenethylamine (PEA) is significantly lower in urine of children with ADHD, whereas amphetamine and methylphenidate normalize, or boost above normal, concentrations of urinary PEA in boys diagnosed with ADHD, or only in responders.

Evidence strength: The association between low urinary PEA and ADHD is supported by multiple observational studies and one systematic meta-analysis of biomarkers. However, no controlled clinical trial of PEA supplementation as a direct treatment for ADHD has been published. The biomarker association does not establish PEA supplementation as an effective treatment.

4.3 Exercise, Physical Activity, and "Runner's High"

Urinary concentrations of phenylacetic acid are increased following exercise, suggesting that phenylethylamine may be involved in the "runner's high," the state of euphoria associated with a level of physical exercise.

Thirty minutes of moderate- to high-intensity physical exercise has been shown to induce an increase in urinary phenylacetic acid, the primary metabolite of phenylethylamine. Two reviews noted a study where the mean 24-hour urinary phenylacetic acid concentration following just 30 minutes of intense exercise rose 77% above its base level; the reviews suggest that phenylethylamine synthesis sharply increases during physical exercise, during which it is rapidly metabolized due to its short half-life of roughly 30 seconds.

Evidence strength: Evidence for PEA's role in the runner's high is indirect — based on urinary metabolite data, not direct measurement of brain PEA concentrations. No controlled human trials have tested PEA supplementation as a means of replicating or enhancing exercise-related euphoria.

4.4 Schizophrenia and Psychosis

Depressed and chronic paranoid schizophrenic patients show decreased and increased PEA urinary excretion, respectively. Parkinsonian patients show decreased urinary PEA excretion.

Five women with primary major bipolar affective disorders had variable and at times very high urinary phenylethylamine (PEA) excretion rates. The clinical picture of these patients was characterized by periodic bizarre behaviors and short psychotic episodes. These patients were generally nonresponsive to usual treatment modalities, and their symptoms were exacerbated by nonspecific monoamine oxidase inhibitors which further increased PEA excretion rates.

Studies on phenylethylamine in schizophrenia have been considered particularly problematic because of the trace amine status of phenylethylamine — small amounts, rapid transit through systems, unstable — which has resulted in technological difficulties in measurement and lack of conformity in values across studies.

Evidence strength: The association between altered PEA levels and schizophrenia is preliminary and methodologically challenged. No clinical intervention trials of PEA supplementation in schizophrenia have been published.

4.5 Parkinson's Disease

Subnormal phenylethylamine levels have been linked to disorders such as attention deficit and depression; the use of selegiline (Deprenyl) in Parkinson's disease may conceivably favor recovery from deficient dopaminergic neurotransmission by a MAO-B inhibitory action that increases central phenylethylamine. Trace amine levels are altered in Parkinsonism, and trace amines are believed to play a role in this condition.

Evidence strength: The relationship is largely inferred from the pharmacodynamics of selegiline (which raises PEA by inhibiting MAO-B). No direct clinical trials of PEA supplementation in Parkinson's disease have been published.

4.6 Migraine Headache

PEA has been postulated to play a role in the etiology of migraine headache. The proposed mechanism involves the vasoconstrictive and vasoactive properties shared by PEA and related trace amines, and the epidemiological observation that chocolate — a dietary source of PEA — is a commonly reported migraine trigger. However, this association remains speculative at the biochemical level.

Evidence strength: The postulated role of PEA in migraine is based on indirect, observational, and theoretical evidence only. No controlled trials have examined supplemental PEA in migraine treatment or prevention.

4.7 Weight Loss and Appetite Suppression

The original class of centrally acting anti-obesity medications was based on phenylethylamine — the chemical backbone for noradrenaline and dopamine. Amphetamine and its derivatives act as sympathomimetic stimulants to regulate signaling of reward and locomotor activity. While the pharmaceutical phenylethylamine derivatives (amphetamines) have well-established anorectic effects, PEA itself as a supplement has not been the subject of formal controlled human weight-loss trials.

A single side effect which could be relevant is that β-PEA has demonstrated appetite-reducing activity, reducing food intake in animal research.

Evidence strength: Animal data only for direct PEA supplementation and weight loss. The broader pharmaceutical evidence from amphetamine derivatives, which share the phenylethylamine backbone, cannot be extrapolated to PEA itself.

4.8 Reward, Reinforcement, and Addiction Research

Research in rodents showed that acute β-PEA increased stereotypic behaviors such as circling and head-twitching responses in mice. In the conditioned place preference (CPP) experiment, β-PEA increased place preference in mice.

TAAR1's unique positioning to exert direct control over dopamine and serotonin neuronal firing and release has profound implications for understanding addiction pathophysiology. TAAR1 has been shown to be potently activated by trace amines such as tyramine and PEA. Catecholamine metabolites and amphetamine analogs are also potent agonists of TAAR1, implicating the receptor in mediating the monoaminergic system and in substance use disorders.

Evidence strength: This area is largely preclinical. TAAR1-directed ligands are in active pharmaceutical development, but translational evidence for PEA supplementation in addiction management is absent.

5. Body Systems and Health Areas Associated with PEA

• Central Nervous System: PEA is synthesized and acts within dopaminergic pathways of the striatum, nucleus accumbens, and mesocorticolimbic system. It modulates mood, attention, reward, and locomotor activity.
• Neuropsychiatric: PEA's impact on attention deficit hyperactivity disorder, depression, and schizophrenia are three examples of psychological disorders where its neurotransmitter role has been studied.
• Cardiovascular: Drugs in the phenylethylamine class elevate the activity of a number of neural pathways, and side effects have been documented including increased blood pressure and heart rate.
• Gastrointestinal: PEA and tyramine in fermented foods are recognized by hTAAR receptors in the gastrointestinal tract, suggesting a physiological role in gut signaling that is under active investigation.
• Neuroendocrine: The link between PEA surges and states of romantic attachment, stress, and intense exercise suggest integration with broader neuroendocrine signaling, though the mechanistic details remain under investigation.

6. Dosage Forms and Reported Dosages

Important context: Because of PEA's rapid degradation by MAO-B, clinically studied oral dosing has consistently employed a MAO-B inhibitor (usually selegiline) co-administered alongside PEA to prevent first-pass elimination. Supplement doses studied or used without a MAO-B inhibitor may have substantially reduced or negligible systemic activity.

• Antidepressant clinical study dosage (Sabelli et al., 1996): Fourteen patients received 10–60 mg orally per day of PEA (with 10 mg/day selegiline), administered in divided doses according to clinical response.
• Selegiline dose used in clinical PEA studies: All patients in the sustained antidepressant study received selegiline 5 mg twice daily plus 10–60 mg of PEA per day, given in divided doses (2.5–20 mg) before 5:00 PM.
• Single oral excretion study: An excretion study of phenylethylamine in humans used a single oral dose of 300 mg.
• Typical supplement label dosage (non-clinical context): As a dietary supplement or powder, a typical dosage is about 100 milligrams to 500 milligrams daily, equivalent to about 1/8 teaspoon of powder.

7. Safety Considerations and Drug Interactions

Rapid Degradation and Oral Bioavailability

In humans, PEA is metabolized by multiple enzyme systems including MAO-A, MAO-B, SSAOs, FMO3, and AANAT. Studies indicate that the PEA found in chocolate is metabolized rapidly by the body, limiting its effect on brain chemistry. The rapid metabolism of phenylethylamine by MAO-B will stop dietary PEA from reaching the brain. The same principle applies to oral PEA supplementation without an MAO-B inhibitor.

Amphetamine-Like Side Effect Profile

Too much phenethylamine might cause side effects similar to the drug amphetamine. Following ingestion of β-PEA, people commonly report a surge of energy, wakefulness, alertness, and heightened senses.

Hypertensive Crisis Risk with MAO Inhibitors

The "cheese reaction" refers to high levels of tyramine as a result of elevated levels of tyrosine in cheese with increased storage times. PEA can be a by-product of the tyrosine decarboxylase reaction because the same enzyme that is capable of converting tyrosine to tyramine can also metabolize phenylalanine to PEA. In individuals taking monoamine oxidase inhibiting drugs, the "cheese reaction" can result in a hypertensive crisis. This is directly relevant to anyone combining PEA supplementation with any class of MAOI.

Psychiatric Contraindications

Use of phenethylamine might cause people with bipolar disorder to convert from depression to mania. Use of phenethylamine might worsen symptoms of schizophrenia, including hallucinations or delusions. This aligns with the neurochemical evidence: chronic paranoid schizophrenic patients show increased PEA urinary excretion, suggesting that further elevating PEA signaling could be detrimental in this population.

Drug Interactions

• MAO Inhibitors (MAOIs) — Major: Co-administration of PEA with any MAOI (nonselective, MAO-A selective, or MAO-B selective) dramatically increases systemic PEA exposure. Treatment with clinically relevant doses of R-(–)-deprenyl (up to 10 mg) that selectively inhibit MAO-B can result in a nearly 100-fold increase in the urinary excretion of β-PEA. This combination was the basis of the clinical antidepressant studies, but it also carries significant risk of hypertensive episodes and excessive stimulant effects.
• Tricyclic Antidepressants (e.g., desipramine) — Moderate: Desipramine can affect how quickly the protein responsible for clearing phenethylamine operates. Taking phenethylamine along with desipramine might increase the levels and effects of phenethylamine. This might cause too much serotonin in the brain and could result in serious side effects including heart problems, shivering, and anxiety.
• Sympathomimetic Agents: Given PEA's catecholaminergic activity, additive cardiovascular effects (tachycardia, elevated blood pressure) are plausible with other sympathomimetic substances; however, formal interaction studies have not been published.

Surgical Precaution

Phenethylamine might affect the central nervous system and could interfere with surgery. A precautionary recommendation is to stop taking phenethylamine at least 2 weeks before a scheduled surgery.

Adulteration Concerns in the Supplement Market

Synthetic phenethylamine (PEA) analogs, such as β-methylphenethylamine (BMPEA) and N,α-diethylphenethylamine (DEPEA), are often found in dietary supplements despite regulations prohibiting their sale. PEA analogs are structurally related to amphetamine, and BMPEA and DEPEA have been shown to produce cardiovascular stimulation mimicking the effects of amphetamine. Consumers should be aware that products labeled as containing PEA or related ingredients may contain undisclosed pharmaceutical analogs.

8. Summary of Evidence Quality

The overall evidence base for beta-phenylethylamine as a dietary supplement is preliminary and largely preclinical. The strongest evidence concerns its role as an endogenous neuromodulator and the biochemical associations between PEA levels and neuropsychiatric states. The most cited clinical finding — the 60% depression response rate — comes from a single small open-label trial. No large randomized controlled trials (RCTs), systematic reviews of RCTs, or Cochrane reviews specifically addressing PEA supplementation in any indication have been published. The discovery in 2001 of the TAAR family triggered a resurgence of interest in trace amines; however, initial optimism quickly faded as the TAAR family presented a series of challenges preventing the use of standard medicinal chemistry and pharmacology technologies, making the translation of findings from model systems to humans problematic.

References

• Rietdorf K et al. β-phenylethylamine, a small molecule with a large impact. PMC / Frontiers in Neuroscience, 2014.
• Sabelli H, Fink P, Fawcett J, Tom C. Sustained antidepressant effect of PEA replacement. J Neuropsychiatry Clin Neurosci. 1996;8(2):168–71. PubMed PMID: 9081552.
• Kim MJ et al. Effects of β-Phenylethylamine on Psychomotor, Rewarding, and Reinforcing Behaviors and Affective State: The Role of Dopamine D1 Receptors. PMC, 2021.
• Sotnikova TD et al. Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. PubMed, 2004.
• Xie Z, Miller GM. Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1. J Pharmacol Exp Ther. 2008;325(2):617–28. PubMed PMID: 18182557.
• Pei Y, Asif-Malik A, Canales JJ. Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications. Front Neurosci. 2016;10:148. PMC4820462.
• Anastasio NC et al. Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders. CNS Drugs / PMC, 2022. PMC8787759.
• Mosnaim AD, Wolf ME. Phenylethylamine in neuropsychiatric disorders. PubMed, 1983. PMID: 6352395.
• Sabelli HC et al. Phenylethylamine excretion in depression. PubMed, 1983. PMID: 6597458.
• Baker GB et al. Phenylethylaminergic mechanisms in attention-deficit disorder. PubMed, 1991. PMID: 2001444.
• Scassellati C et al. Phenylethylamine Excretion in Attention Deficit Disorder. ScienceDirect, 2012.
• Karoum F et al. Fluctuating high urinary phenylethylamine excretion rates in some bipolar affective disorder patients. ScienceDirect, 1982.
• Moises HW et al. Urinary phenylethylamine correlates positively with hypomania, and negatively with depression, paranoia, and social introversion on the MMPI. Eur Arch Psychiatry Neurol Sci. 1986;236(2):83–7.
• Xie Z, Westmoreland SV, Miller GM. β-Phenylethylamine Alters Monoamine Transporter Function via Trace Amine-Associated Receptor 1. ScienceDirect / J Pharmacol Exp Ther, 2008.
• Bray GA et al. Centrally Acting Drugs for Obesity: Past, Present, and Future. PMC, 2018. PMC6095132.
• NCATS Inxight Drugs — PHENETHYLAMINE. National Center for Advancing Translational Sciences, NIH.
• NIH Dietary Supplement Label Database — Phenylethylamine. NIH Office of Dietary Supplements.
• Nagatsu T et al. Importance of β-phenylethylamine (PEA) neuronal system, equivalent to D-neuron system and TAAR1 ligand neuron system. PMC, 2025. PMC11814602.
• RxList. Phenethylamine: Health Benefits, Side Effects, Uses, Dose & Precautions. WebMD/RxList.
• Schwarcz J. The "Chemical of Love." McGill University Office for Science and Society, 2020.
• Schwarcz J. Phenylethylamine is Said To Stoke the Fire of Love. Here Comes the Water Bucket. McGill University Office for Science and Society, 2024.
• Ohta H et al. Tyramine and β-phenylethylamine, from fermented food products, as agonists for the human trace amine-associated receptor 1 (hTAAR1) in the stomach. Biosci Biotechnol Biochem. 2017.
• Liu JF, Li JX. TAAR1 and Psychostimulant Addiction. PMC, 2021. PMC7845786.
• Hanson J. Phenylethylamine. University of Bristol, School of Chemistry, Molecule of the Month.